@article{ref1,
title="Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam",
journal="European journal of clinical pharmacology",
year="1985",
author="O'Boyle, C. and Lambe, R. and Darragh, A.",
volume="29",
number="1",
pages="105-108",
abstract="The novel benzodiazepine derivative, meclonazepam (3-methylclonazepam) has been found to be orally effective at high doses against all stages of schistosomiasis. Animals studies have shown it to have a high therapeutic index and a profile of behavioural activity typical of the benzodiazepines. The effects of single oral doses of meclonazepam, 1, 2 and 4 mg on central arousal, psychomotor performance and subjective mood were studied in two double-blind placebo controlled studies in healthy volunteers. In doses exceeding 1 mg, meclonazepam caused marked dose-related impairment in cognitive and psychomotor functions as well as shifts in mood reflecting sedation and ataxia. These effects were most prominent in the first 3 h after administration, with moderate sedation still present 6 h after the 4 mg dose. The implications of these findings for the use of benzodiazepine agents in the treatment of schistosomiasis are discussed.<p /><p>Language: en</p>",
language="en",
issn="0031-6970",
doi="",
url="http://dx.doi.org/"
}